Details of the Drug
General Information of Drug (ID: DM958EN)
Drug Name |
8-Piperazin-1-yl-imidazo[1,2-a]pyrazine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
76537-53-6; 8-(1-Piperazinyl)imidazo(1,2-a)pyrazine; 8-(1-piperazinyl)imidazo[1,2-a]pyrazine; CHEMBL331036; 8-piperazin-1-ylimidazo[1,2-a]pyrazine; 8-Pdpr; Imidazo(1,2-a)pyrazine, 8-(1-piperazinyl)-; Imidazo[1,2-a]pyrazine, 8-(1-piperazinyl)-; 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine; AC1L2YVL; 8-(piperazin-1-yl)imidazo[1,2-a]pyrazine; AC1Q4X6M; SCHEMBL5496661; AC1Q1I52; CTK5E3085; DTXSID50227346; ZINC5117657; BDBM50002151; AKOS024075563; FT-0756627; Imidazo[1,2-a]pyrazine,8-(1-piperazinyl)-; A839966
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 203.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||